FDANews
FDAnews Drug Daily Bulletin

House Democrats Press CMS on Details of CAR-T Therapy Deal

Sept. 20, 2017

A group of House Democrats sought further information from CMS on pricing for Novartis’ newly approved CAR-T cancer therapy.

In the letter, Rep. Lloyd Doggett (Texas) and eight colleagues asked CMS administrator Seema Verma for information on Novartis’ potential profits on the drug, including how many Medicare and Medicaid patients will receive it in the next year, five years and 10 years.

The lawmakers also requested details of the agency’s payment deal, under which CMS will only pay Novartis if there is a response to the drug by the end of the first month. The representatives asked for the rationale behind the one-month response period as well as the agreed-upon definition of success.

View today's stories